 SAN DIEGO, Nov. 30, 2020 GLOBE NEWSWIRE -- Otonomy, Inc. Nasdaq: OTIC, a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided updates regarding the statistical analysis plan for the ongoing Phase 3 trial of OTIVIDEX in Ménières disease, and outlined plans for a Phase 2 trial of OTO-313 in tinnitus. 